


Please cite the Published Version

Smith, Madeleine Claire, Hudson, Claire, White, Steve , Kimura, Tomomi, Sala-Newby, Graciela, Newby, Andrew and Bond, Mark (2017) Camp divergently regulates nuclear actin and myocardin-related transcription factor (MKL1) in VSMCS and ECS. *Atherosclerosis*, 263. e77-e77. ISSN 0021-9150

DOI: <https://doi.org/10.1016/j.atherosclerosis.2017.06.256>

Publisher: Elsevier

Version: Accepted Version

Downloaded from: <https://e-space.mmu.ac.uk/625356/>

Usage rights:  In Copyright

Additional Information: This is an Author Accepted Manuscript of a paper accepted for publication in *Atherosclerosis* published by and copyright Elsevier.

Enquiries:

If you have questions about this document, contact openresearch@mmu.ac.uk. Please include the URL of the record in e-space. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from <https://www.mmu.ac.uk/library/using-the-library/policies-and-guidelines>)

cAMP Divergently Regulates Nuclear Actin And Myocardin related Transcription Factor (Mkl1) In VSMCs and ECs

Madeleine Claire Smith, Claire Hudson, Steve White, Tomomi Kimura, Graciela Sala-Newby, Andrew Newby, Mark Bond. University of Bristol, Bristol, United Kingdom

Aim: Proliferation and migration of VSMC and EC contribute positively and negatively, respectively, to intimal hyperplasia. Moreover, current generation anti-mitotics increase thrombotic risk by impairing endothelial regrowth. Hence, targets for VSMC-specific anti-proliferative/migratory agents are required. Here we investigated the effect of cAMP-induced nuclear actin remodelling on the serum response factor (SRF) co-factor Megakaryoblastic Leukemia-1 (MKL1) in VSMC and EC.

Methods: Rat aortic VSMC (RaVSMCs) and human coronary artery ECs (HCAECs) were treated with physiological cAMP activators BAY60-6583 and Cicaprost. G-actin was detected by Dnase1. Migration analysis was performed using IncuCyteZOOM live-cell imaging and proliferation measured by bromodeoxyuridine (BrdU).

Results: cAMP elevation increased nuclear G-actin in RaVSMCs (1.54 ± 0.16 fold, $n=6$, $p<0.05$), which inhibited proliferation and migration. By contrast, cAMP did not affect nuclear G-actin levels or inhibit proliferation and migration in HCAECs. Elevated cAMP inhibited mitogen-induced nuclear translocation of MKL1 in RaVSMC (from 70.4 ± 2.92 to $4.27 \pm 2.55\%$, $n=4$, $p<0.001$) but not HCAECs, which was replicated by expression of an unpolymerisable nuclear actin mutant (NLS-ACTIN-R62D). cAMP elevation or expression of NLS-ACTIN-R62D significantly inhibited SRF-dependent reporter activity and mRNA expression of pro-proliferative/migratory MKL1 genes in VSMCs but not HCAECs. MKL1 silencing or NLS-ACTIN-R62D significantly inhibited proliferation and migration of RaVSMC. In the human saphenous vein organ culture model, MKL1 inhibition significantly reduced intimal thickness (to $0.134 \pm 0.088 \mu\text{m}$ of control, $n=4$, $p<0.01$) and intimal proliferation (to $0.272 \pm 0.044\%$ of control, $n=4$, $p<0.001$).

Conclusions: These data demonstrate cAMP-dependent increases in nuclear G-actin inactivate MKL1 and inhibit proliferation/migration of VSMC but not EC. Further elucidation of this pathway promises to identify targets for specific inhibition of VSMC proliferation/migration.